Neuried/Nesle, 8 July 2026 – AMSilk, a global leader in biotech produced silk materials, today announced a significant expansion of its partnership with Ajinomoto Foods Europe (AFE), marking a key step in scaling the industrial production of its silk proteins. Building on the collaboration first established in 2023, the two companies have now entered into […]
Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data Introduces a first-of-its-kind living vascular access solution for patients requiring hemodialysis EINDHOVEN, The Netherlands – 7 July, 2026 – Xeltis, a leading developer of transformative implants […]
Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor types Myricx Bio’s first-in-class NMTi payload platform is designed to improve the therapeutic […]
Lund, Sweden, July 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled “Don’t Be So Sensitive – Bringing Kidneys to the Over-Sensitized” with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at […]
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice > 50% of target enrollment reached across 20 sites in the United States EINDHOVEN, The Netherlands – 2 July, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation […]
